This test provides an estimation of total aerobic bacteria and yeasts/molds and absence of designated microbial species in all types of pharmaceutical articles from raw materials to finished products following USP 61 and USP 62.
Related to the microbial limits test, iuvo is able to perform the USP 2021 and 2022 assays, which outline a similar procedure for nutritional and dietary supplements. All assays result in the determination of the total aerobic bacterial and yeast/mold counts, as well as the absence of specific organisms identified as objectionable for each group of test articles.
